Literature DB >> 29769329

Isolation of state-dependent monoclonal antibodies against the 12-transmembrane domain glucose transporter 4 using virus-like particles.

David F Tucker1, Jonathan T Sullivan1, Kimberly-Anne Mattia1, Christine R Fisher1, Trevor Barnes1, Manu N Mabila1, Rona Wilf1, Chidananda Sulli1, Meghan Pitts1, Riley J Payne1, Moniquetta Hall1, Duncan Huston-Paterson1, Xiaoxiang Deng1, Edgar Davidson1, Sharon H Willis1, Benjamin J Doranz1, Ross Chambers1, Joseph B Rucker2.   

Abstract

The insulin-responsive 12-transmembrane transporter GLUT4 changes conformation between an inward-open state and an outward-open state to actively facilitate cellular glucose uptake. Because of the difficulties of generating conformational mAbs against complex and highly conserved membrane proteins, no reliable tools exist to measure GLUT4 at the cell surface, follow its trafficking, or detect the conformational state of the protein. Here we report the isolation and characterization of conformational mAbs that recognize the extracellular and intracellular domains of GLUT4, including mAbs that are specific for the inward-open and outward-open states of GLUT4. mAbs against GLUT4 were generated using virus-like particles to present this complex membrane protein in its native conformation and using a divergent host species (chicken) for immunization to overcome immune tolerance. As a result, the isolated mAbs recognize conformational epitopes on native GLUT4 in cells, with apparent affinities as high as 1 pM and with specificity for GLUT4 across the human membrane proteome. Epitope mapping using shotgun mutagenesis alanine scanning across the 509 amino acids of GLUT4 identified the binding epitopes for mAbs specific for the states of GLUT4 and allowed the comprehensive identification of the residues that functionally control the GLUT4 inward-open and outward-open states. The mAbs identified here will be valuable molecular tools for monitoring GLUT4 structure, function, and trafficking, for differentiating GLUT4 conformational states, and for the development of novel therapeutics for the treatment of diabetes.

Entities:  

Keywords:  GLUT4; chicken; lipoparticles; monoclonal antibody; phage display

Mesh:

Substances:

Year:  2018        PMID: 29769329      PMCID: PMC5984492          DOI: 10.1073/pnas.1716788115

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  50 in total

1.  Immunolocalization of glucose transporter GLUT4 within human skeletal muscle.

Authors:  J E Friedman; R W Dudek; D S Whitehead; D L Downes; W R Frisell; J F Caro; G L Dohm
Journal:  Diabetes       Date:  1991-01       Impact factor: 9.461

2.  Cysteine-scanning mutagenesis and substituted cysteine accessibility analysis of transmembrane segment 4 of the Glut1 glucose transporter.

Authors:  Mike Mueckler; Carol Makepeace
Journal:  J Biol Chem       Date:  2005-09-19       Impact factor: 5.157

3.  Regulation of β2-adrenergic receptor function by conformationally selective single-domain intrabodies.

Authors:  Dean P Staus; Laura M Wingler; Ryan T Strachan; Soren G F Rasmussen; Els Pardon; Seungkirl Ahn; Jan Steyaert; Brian K Kobilka; Robert J Lefkowitz
Journal:  Mol Pharmacol       Date:  2013-12-06       Impact factor: 4.436

4.  Quantitative Analysis of Human Red Blood Cell Proteome.

Authors:  Agata H Bryk; Jacek R Wiśniewski
Journal:  J Proteome Res       Date:  2017-07-24       Impact factor: 4.466

5.  Characterisation of glucose transporter (GLUT) gene expression in broiler chickens.

Authors:  T Kono; M Nishida; Y Nishiki; Y Seki; K Sato; Y Akiba
Journal:  Br Poult Sci       Date:  2005-08       Impact factor: 2.095

Review 6.  Nanobody stabilization of G protein-coupled receptor conformational states.

Authors:  Jan Steyaert; Brian K Kobilka
Journal:  Curr Opin Struct Biol       Date:  2011-07-21       Impact factor: 6.809

7.  Molecular dynamics simulation studies of GLUT4: substrate-free and substrate-induced dynamics and ATP-mediated glucose transport inhibition.

Authors:  Suma Mohan; Aswathy Sheena; Ninu Poulose; Gopalakrishnapillai Anilkumar
Journal:  PLoS One       Date:  2010-12-03       Impact factor: 3.240

8.  Mechanism of inhibition of human glucose transporter GLUT1 is conserved between cytochalasin B and phenylalanine amides.

Authors:  Khyati Kapoor; Janet S Finer-Moore; Bjørn P Pedersen; Laura Caboni; Andrew Waight; Roman C Hillig; Peter Bringmann; Iring Heisler; Thomas Müller; Holger Siebeneicher; Robert M Stroud
Journal:  Proc Natl Acad Sci U S A       Date:  2016-04-12       Impact factor: 11.205

9.  The Phyre2 web portal for protein modeling, prediction and analysis.

Authors:  Lawrence A Kelley; Stefans Mezulis; Christopher M Yates; Mark N Wass; Michael J E Sternberg
Journal:  Nat Protoc       Date:  2015-05-07       Impact factor: 13.491

10.  Structure and mechanism of the mammalian fructose transporter GLUT5.

Authors:  Norimichi Nomura; Grégory Verdon; Hae Joo Kang; Tatsuro Shimamura; Yayoi Nomura; Yo Sonoda; Saba Abdul Hussien; Aziz Abdul Qureshi; Mathieu Coincon; Yumi Sato; Hitomi Abe; Yoshiko Nakada-Nakura; Tomoya Hino; Takatoshi Arakawa; Osamu Kusano-Arai; Hiroko Iwanari; Takeshi Murata; Takuya Kobayashi; Takao Hamakubo; Michihiro Kasahara; So Iwata; David Drew
Journal:  Nature       Date:  2015-09-30       Impact factor: 49.962

View more
  11 in total

Review 1.  Thirty sweet years of GLUT4.

Authors:  Amira Klip; Timothy E McGraw; David E James
Journal:  J Biol Chem       Date:  2019-06-07       Impact factor: 5.157

2.  Sites of vulnerability in HCV E1E2 identified by comprehensive functional screening.

Authors:  Jennifer M Pfaff-Kilgore; Edgar Davidson; Kathryn Kadash-Edmondson; Mayda Hernandez; Erin Rosenberg; Ross Chambers; Matteo Castelli; Nicola Clementi; Nicasio Mancini; Justin R Bailey; James E Crowe; Mansun Law; Benjamin J Doranz
Journal:  Cell Rep       Date:  2022-05-24       Impact factor: 9.995

3.  GPC2-CAR T cells tuned for low antigen density mediate potent activity against neuroblastoma without toxicity.

Authors:  Sabine Heitzeneder; Kristopher R Bosse; Zhongyu Zhu; Doncho Zhelev; Robbie G Majzner; Molly T Radosevich; Shaurya Dhingra; Elena Sotillo; Samantha Buongervino; Guillem Pascual-Pasto; Emily Garrigan; Peng Xu; Jing Huang; Benjamin Salzer; Alberto Delaidelli; Swetha Raman; Hong Cui; Benjamin Martinez; Scott J Bornheimer; Bita Sahaf; Anya Alag; Irfete S Fetahu; Martin Hasselblatt; Kevin R Parker; Hima Anbunathan; Jennifer Hwang; Min Huang; Kathleen Sakamoto; Norman J Lacayo; Dorota D Klysz; Johanna Theruvath; José G Vilches-Moure; Ansuman T Satpathy; Howard Y Chang; Manfred Lehner; Sabine Taschner-Mandl; Jean-Phillipe Julien; Poul H Sorensen; Dimiter S Dimitrov; John M Maris; Crystal L Mackall
Journal:  Cancer Cell       Date:  2021-12-30       Impact factor: 38.585

Review 4.  Improving antibody drug development using bionanotechnology.

Authors:  Emily K Makowski; John S Schardt; Peter M Tessier
Journal:  Curr Opin Biotechnol       Date:  2021-12-07       Impact factor: 10.279

5.  Golden Gate assembly with a bi-directional promoter (GBid): A simple, scalable method for phage display Fab library creation.

Authors:  Karuppiah Chockalingam; Zeyu Peng; Christine N Vuong; Luc R Berghman; Zhilei Chen
Journal:  Sci Rep       Date:  2020-02-19       Impact factor: 4.379

Review 6.  Polyreactivity and polyspecificity in therapeutic antibody development: risk factors for failure in preclinical and clinical development campaigns.

Authors:  Orla Cunningham; Martin Scott; Zhaohui Sunny Zhou; William J J Finlay
Journal:  MAbs       Date:  2021 Jan-Dec       Impact factor: 5.857

7.  The third-generation anti-CD30 CAR T-cells specifically homing to the tumor and mediating powerful antitumor activity.

Authors:  Shangkun Zhang; Chaojiang Gu; Lifang Huang; Han Wu; Jiangzhou Shi; Zijian Zhang; Yong Zhou; Jingjiao Zhou; Yang Gao; Jiaxing Liu; Yingqi Leng; Xiyu Liu; Qinxing Zhang; Liang Huang; Xiqin Tong; Ken H Young; Jiapeng Li; Haichuan Zhu; Tongcun Zhang
Journal:  Sci Rep       Date:  2022-06-21       Impact factor: 4.996

8.  A humanized nanobody phage display library yields potent binders of SARS CoV-2 spike.

Authors:  Ying Fu; Juliana da Fonseca Rezende E Mello; Bryan D Fleming; Alex Renn; Catherine Z Chen; Xin Hu; Miao Xu; Kirill Gorshkov; Quinlin Hanson; Wei Zheng; Emily M Lee; Lalith Perera; Robert Petrovich; Manisha Pradhan; Richard T Eastman; Zina Itkin; Thomas B Stanley; Allen Hsu; Venkata Dandey; Kedar Sharma; William Gillette; Troy Taylor; Nitya Ramakrishnan; Shelley Perkins; Dominic Esposito; Eunkeu Oh; Kimihiro Susumu; Mason Wolak; Marc Ferrer; Matthew D Hall; Mario J Borgnia; Anton Simeonov
Journal:  PLoS One       Date:  2022-08-10       Impact factor: 3.752

9.  Structure and mechanism of blood-brain-barrier lipid transporter MFSD2A.

Authors:  Chase A P Wood; Jinru Zhang; Deniz Aydin; Yan Xu; Benjamin J Andreone; Urs H Langen; Ron O Dror; Chenghua Gu; Liang Feng
Journal:  Nature       Date:  2021-08-04       Impact factor: 49.962

10.  A GPC2 antibody-drug conjugate is efficacious against neuroblastoma and small-cell lung cancer via binding a conformational epitope.

Authors:  Swetha Raman; Samantha N Buongervino; Maria V Lane; Doncho V Zhelev; Zhongyu Zhu; Hong Cui; Benjamin Martinez; Daniel Martinez; Yanping Wang; Kristen Upton; Khushbu Patel; Komal S Rathi; Carmen T Navia; Daniel B Harmon; Yimei Li; Bruce Pawel; Dimiter S Dimitrov; John M Maris; Jean-Philippe Julien; Kristopher R Bosse
Journal:  Cell Rep Med       Date:  2021-07-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.